TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Inclusion criteria include: * Considered platinum refractory or resistant according to standard criteria * Progressed during or following completion of one second-line treatment with Doxil/Caelyx or Hycamtin * Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer * Measurable disease according to RECIST criteria with documented tumor progression Exclusion criteria include: * Treatment with second-line chemotherapy other than Doxil/Caelyx or Hycamtin * History of whole pelvis radiation therapy within 12 months of enrollment * Clinically significant cardiac disease * Evidence of gross hematuria at the time of study entry * Any signs of intestinal obstruction interfering with nutrition at the time of study entry * Pregnant or lactating women